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Fluconazole in vitro susceptibility test results for 256,882 isolates of Candida spp. were collected from 142
sites in 41 countries from June 1997 to December 2007. Data were collected for 197,619 isolates tested with
voriconazole from 2001 to 2007. A total of 31 different species of Candida were isolated. Increased rates of
isolation of the common non-albicans species C. glabrata (10.2% to 11.7%), C. tropicalis (5.4% to 8.0%), and C.
parapsilosis (4.8% to 5.6%) were noted when the time periods 1997 to 2000 and 2005 to 2007 were compared.
Investigators tested clinical isolates of Candida spp. by the CLSI M44-A disk diffusion method. Overall, 90.2%
of Candida isolates tested were susceptible (S) to fluconazole; however, 13 of 31 species identified exhibited
decreased susceptibility (<75% S), similar to that seen with the resistant (R) species C. glabrata and C. krusei.
Among 197,619 isolates of Candida spp. tested against voriconazole, 95.0% were S and 3% were R. About 30%
of fluconazole-R isolates of C. albicans, C. glabrata, C. tropicalis, C. rugosa, C. lipolytica, C. pelliculosa, C. apicola,
C. haemulonii, C. humicola, C. lambica, and C. ciferrii remained S to voriconazole. An increase in fluconazole
resistance over time was seen with C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pelliculosa.
Among the emerging fluconazole-R species were C. guilliermondii (11.4% R), C. inconspicua (53.2% R), C. rugosa
(41.8% R), and C. norvegensis (40.7% R). The rates of isolation of C. rugosa, C. inconspicua, and C. norvegensis
increased by 5- to 10-fold over the 10.5-year study period. C. guilliermondii and C. rugosa were most prominent
in Latin America, whereas C. inconspicua and C. norvegensis were most common in Eastern European countries.
This survey identifies several less-common species of Candida with decreased susceptibility to azoles. These
organisms may pose a future threat to optimal antifungal therapy and underscore the importance of prompt
and accurate species identification and antifungal susceptibility testing.
Antifungal susceptibility testing is playing an increasing role
as a means to track the development of antifungal resistance in
epidemiological studies (2, 10, 12, 17, 27, 45–47, 55, 63). One
of the important by-products of the standardization of antifun-
gal susceptibility testing has been the ability to conduct sur-
veillance for antifungal resistance using uniform methods (44).
Meaningful large-scale surveys of antifungal susceptibility and
resistance conducted over time would not be possible without
a standardized broth microdilution (BMD) or disk diffusion
(DD) method for performing the in vitro studies (12, 38, 60).
Global surveillance programs such as the ARTEMIS antifun-
gal surveillance program for DD testing (49, 57, 60) and MIC
testing (12, 13), the European Confederation of Medical My-
cology (ECMM) survey of candidemia (68), and the SENTRY
Antifungal Surveillance Program (36–38) promote the use of
standardized DD and BMD methods and provide useful and
consistent antifungal susceptibility data from a broad interna-
tional network of hospitals and laboratories.
The ARTEMIS global antifungal surveillance program is
among the most comprehensive and long-running fungal sur-
veillance programs (12, 45, 57, 58, 60). The ARTEMIS pro-
gram was designed to address many of the potential limitations
of resistance surveillance studies (26): (i) it is both longitudinal
(1997 to present) and global (142 participating sites in 41
countries) in scope, (ii) it employs standardized DD (7) and
BMD (9) antifungal susceptibility test methods, (iii) both in-
ternal quality control (QC) performed in each participating
laboratory and external quality assurance measures are used to
validate test results (48, 50, 61), (iv) results are recorded elec-
tronically using the Biomic image analysis plate reader (Giles
Scientific, Santa Barbara, CA) and are stored in a central
database, and (v) both Candida and non-Candida (60) yeast
isolates obtained from consecutive clinical samples from all
body sites are tested locally, thus avoiding misleading results
based on biased selective testing. Thus, the ARTEMIS pro-
gram generates massive amounts of data that have been exter-
nally validated and that can be used to identify temporal and
geographic trends in the species distribution of Candida and
other opportunistic yeasts, as well as the resistance profiles of
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these organisms to fluconazole and voriconazole as deter-
mined by standardized Clinical and Laboratory Standards In-
stitute (CLSI) DD methods.
In the present study, we expand the ARTEMIS database to
include the time period from June 1997 through December
2007 and a total of 256,882 isolates of Candida from 142 study
sites in 41 countries. We provide comparative susceptibility
data for fluconazole and voriconazole for more than 190,000
isolates collected from 2001 to 2007 and include an analysis of
resistance rates by year, geographic location, hospital location,
and specimen type for selected species.
MATERIALS AND METHODS
Organisms and test sites. A total of 256,882 isolates of Candida obtained from
142 different medical centers in the Asia-Pacific region (24 sites), Latin America
(16 sites), Europe (18 sites), the Africa/Middle East region (11 sites), and North
America (13 sites) were collected and tested against fluconazole between June
1997 and December 2007. In addition, 197,619 isolates from 133 institutions were
tested against voriconazole between 2001 and 2007. Approximately 80% of the
study sites participated in the survey for 3 or more years (average duration of
participation, 4.5 years; range, 1 to 10.5 years).
All yeasts considered pathogens from all body sites (e.g., blood, normally
sterile body fluids [NSBF], deep tissue, genital tract, gastrointestinal tract, re-
spiratory tract, urine, and skin and soft tissue) and isolates from patients in all
in-hospital and outpatient locations during the study period were tested. Yeasts
considered by the local site investigator to be colonizers (i.e., not associated with
an obvious pathology) were excluded, as were duplicate isolates from a given
patient (same species and same susceptible or resistant biotype profile within any
7-day period). The identification of isolates was performed locally in accordance
with each site’s routine methods. The majority (76%) of the study sites employed
one or more commercially available yeast identification systems (API, Vitek,
and/or MicroScan) supplemented by classical biochemical and molecular meth-
ods, and the remainder used the classical methods alone (19, 21).
Susceptibility test method. Disk diffusion (DD) testing of fluconazole and
voriconazole was performed as described previously (20, 57) and in CLSI doc-
ument M44-A (7). Agar plates (90-, 100-, or 150-mm diameter) containing
Mueller-Hinton agar (obtained locally at all sites) supplemented with 2% glucose
and 0.5 g of methylene blue per ml at a depth of 4.0 mm were used. The agar
surface was inoculated by using a swab dipped in a cell suspension adjusted to the
turbidity of a 0.5 McFarland standard. Fluconazole (25 g) and voriconazole (1
g) disks (Becton Dickinson, Sparks, MD) were placed onto the surfaces of the
inoculated plates, and the plates were incubated in air at 35 to 37°C and read at
18 to 24 h. Zone diameter endpoints were read at 80% growth inhibition by using
a Biomic image analysis plate reader system (Giles Scientific) (20, 49, 57, 60).
The interpretive criteria for the fluconazole and voriconazole DD tests were
those of the CLSI (8, 51, 52): susceptible (S), zone diameters of 19 mm
(fluconazole) and 17 mm (voriconazole); susceptible dose dependent (SDD),
zone diameters of 15 to 18 mm (fluconazole) and 14 to 16 mm (voriconazole);
and resistant (R), zone diameters of 14 mm (fluconazole) and 13 mm (vori-
conazole). The corresponding MIC breakpoints (8, 51, 52) are as follows; S,
MICs of8 g/ml (fluconazole) and1 g/ml (voriconazole); SDD, MICs of 16
to 32 g/ml (fluconazole) and 2 g/ml (voriconazole); and R, MICs of64 g/ml
(fluconazole) and 4 g/ml (voriconazole).
QC. Quality control (QC) was performed in accordance with CLSI document
M44-S2 (8) by using Candida albicans ATCC 90029 and C. parapsilosis ATCC
22019. Totals of 15,413 and 14,987 QC results were obtained for fluconazole and
voriconazole, respectively, more than 94% of which were within the acceptable
limits.
Analysis of results. All yeast DD test results were read by electronic image
analysis and interpreted and recorded with the Biomic plate reader system (Giles
Scientific). Test results were sent by e-mail to Giles Scientific for analysis. The
zone diameter, susceptibility category (S, SDD, or R), and QC test results were
all recorded electronically. Patient and doctor names, duplicate test results (same
patient, same species, and same biotype results), and uncontrolled results were
automatically eliminated prior to analysis. In the present study, fluconazole and
voriconazole S, SDD, and R results for each species of Candida were stratified
by year of collection, geographic region, clinical specimen type, and hospital
location. Because large numbers would predispose the study to type I error, we
did not perform formal significance testing; rather, we focused on clinically and
microbiologically relevant trends.
RESULTS
Isolation rates by species. A total of 256,882 isolates of
Candida spp. were collected and tested at 142 study sites be-
tween June 1997 and December 2007 (Table 1). A total of 31
different species of Candida were isolated, of which C. albicans
was the most common (overall, 65.3% of all Candida spp.). A
decreased rate of isolation of C. albicans was noted when the
first 3 years of the study (1997 to 2000, 70.9% of all Candida
spp.) were compared with the subsequent years (2001 to 2004,
62.9%; 2005 to 2007, 65.0% of all Candida spp.), although the
rates of isolation over the most recent 3-year period did not
show a continued declining trend. In contrast to that observed
for C. albicans, increased rates of isolation of the common
non-albicans species C. glabrata (10.2% to 11.7%), C. tropicalis
(5.4% to 8.0%), and C. parapsilosis (4.8% to 5.6%) were noted
when the time periods 1997 to 2000 and 2005 to 2007 were
compared. The rates of isolation of C. krusei, C. guilliermondii,
C. lusitaniae, C. kefyr, and C. famata did not vary significantly,
whereas those of fluconazole-resistant species C. rugosa, C.
inconspicua, and C. norvegensis increased by 5- to 10-fold over
the 10.5-year study period. The rates of isolation of the re-
maining 19 species remained quite low; however, the increased
detection of these species is further evidence of more vigorous
efforts to identify clinical isolates of Candida to the species
level in recent years.
Geographic variation in the frequency of Candida species.
The five most common species of Candida, C. albicans, C.
glabrata, C. tropicalis, C. parapsilosis, and C. krusei, accounted
for 92% of all isolates reported during the most recent 7 years
of the study (Table 2). Although these five species were prom-
inent in each of the five geographic regions, the frequency and
rank order varied considerably across the regions. Whereas C.
albicans accounted for 64% to 67% of all Candida isolates in
the Asia-Pacific, European, and Africa/Middle East regions, it
was less prominent in Latin America (51.8%) and North
America (48.9%). An even greater disparity was seen with C.
glabrata, which was fourth in rank order in Latin America,
accounting for only 7.4% of the isolates, and was second in the
rank order in North America, accounting for 21.1% of the
isolates from that region. Likewise, C. tropicalis was consider-
ably more prominent in the Asia-Pacific (11.7%) and Latin
American (13.2%) regions than in the other regions (range,
4.9% to 7.3%). C. parapsilosis, a prominent cause of catheter-
related infection (69), was an infrequent cause of invasive
candidiasis (IC) in Europe (4.2%) compared to either Latin
America (10.3%) or North America (13.6%).
Among the less common species of Candida isolated from
clinical specimens, four stand out due to their decreased sus-
ceptibility to azoles and other antifungal agents and their grad-
ual emergence as causes of invasive candidiasis (3, 11, 14, 53,
54, 62): C. guilliermondii, C. inconspicua, C. rugosa, and C.
norvegensis (Table 2). Notably, each of these species appears to
be more prominent in some geographic regions than in others:
C. guilliermondii and C. rugosa in Latin America and C. incon-
spicua and C. norvegensis in Europe (Table 2).
Fluconazole and voriconazole susceptibilities of Candida
spp. Table 3 summarizes the in vitro susceptibilities of 201,653
and 197,619 isolates of Candida spp. to fluconazole and vori-
conazole, respectively, as determined by CLSI DD testing (7).
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These isolates were obtained from 133 institutions during the
period from 2001 through 2007. The percentages of isolates in
each category (S, SDD, and R) were 90.2%, 3.6%, and 6.2%
and 95.0%, 2.0%, and 3.0% for fluconazole and voriconazole,
respectively. Fluconazole was most active (90% S) against C.
albicans (98.0% S), C. tropicalis (91.0% S), C. parapsilosis
(93.2% S), C. lusitaniae (92.1% S), C. kefyr (96.5% S), C.
dubliniensis (96.1% S), C. apicola (98.2% S), C. intermedia
(95.8% S), C. pulcherrima (100% S), C. colliculosa (100% S), C.
holmii (100% S), and C. sphaerica (100% S). Decreased sus-
TABLE 1. Species distribution of Candida isolates over 10.5 yearsa
Organism
Isolates tested by period:
1997–2000 2001–2004 2005–2007 1997–2007
No. % of total No. % oftotal No.
% of
total No.
% of
total
Candida albicans 39,152 70.9 71,027 62.9 57,598 65.0 167,777 65.3
C. glabrata 5,634 10.2 12,963 11.5 10,342 11.7 28,939 11.3
C. tropicalis 2,996 5.4 8,496 7.5 7,050 8.0 18,542 7.2
C. parapsilosis 2,633 4.8 7,783 6.9 5,005 5.6 15,421 6.0
C. krusei 1,207 2.2 2,840 2.5 2,239 2.5 6,286 2.4
C. guilliermondii 367 0.7 902 0.8 508 0.6 1,777 0.7
C. lusitaniae 276 0.5 674 0.6 559 0.6 1,509 0.6
C. kefyr 182 0.3 527 0.5 517 0.6 1,226 0.5
C. inconspicua 9 0.02 276 0.2 290 0.3 575 0.2
C. famata 123 0.2 375 0.3 247 0.3 745 0.3
C. rugosa 35 0.06 469 0.4 134 0.2 638 0.2
C. dubliniensis 1 0.01 113 0.1 197 0.2 311 0.1
C. norvegensis 11 0.02 135 0.1 113 0.1 259 0.1
C. lipolytica 7 0.01 80 0.07 50 0.06 137 0.05
C. sake 20 0.02 67 0.08 87 0.03
C. pelliculosa 1 0.01 47 0.04 40 0.05 88 0.03
C. apicola 57 0.06 57 0.02
C. zeylanoides 4 0.01 50 0.04 20 0.02 74 0.03
C. valida 9 0.01 12 0.01 21 0.01
C. intermedia 10 0.01 14 0.01 24 0.01
C. pulcherrima 6 0.01 8 0.01 14 0.01
C. haemulonii 6 0.01 3 0.01 9 0.01
C. stellatoidea 7 0.01 7 0.01
C. utilis 6 0.01 6 0.01
C. humicola 2 0.01 4 0.01 6 0.01
C. lambica 5 0.01 5 0.01
C. ciferrii 2 0.01 2 0.01
C. colliculosa 2 0.01 2 0.01
C. holmii 1 0.01 1 0.01
C. marina 1 0.01 1 0.01
C. sphaerica 1 0.01 1 0.01
Candida spp. NOSb 2,591 4.7 6,186 5.5 3,558 4.0 12,335 4.8
Total 55,229 100.0 112,996 100.0 88,647 100.0 256,882 100.0
a Includes all specimen types and all locations in hospitals from 142 institutions in 41 countries.
b Candida spp. NOS, Candida species not otherwise identified.
TABLE 2. Geographic variation in frequency of common and uncommon species of Candida: ARTEMIS, 2001 to 2007a
Species
Species distribution (%) by region (total no. of isolates)b:
APAC
(44,674)
EU
(109,643)
AF/ME
(8,259)
LAM
(27,395)
NAM
(11,682)
Total
(201,653)
C. albicans 64.4 67.9 67.1 51.8 48.9 63.8
C. glabrata 12.6 11.3 8.8 7.4 21.1 11.6
C. tropicalis 11.7 4.9 6.6 13.2 7.3 7.7
C. parapsilosis 7.4 4.2 6.0 10.3 13.6 6.3
C. krusei 1.2 3.4 1.6 1.4 3.1 2.5
C. guilliermondii 0.4 0.5 0.1 2.2 0.5 0.7
C. inconspicua 0.1 0.5 0.1 0.1 0.3
C. rugosa 0.4 0.1 0.1 1.2 0.1 0.3
C. norvegensis 0.1 0.2 0.1 0.1 0.2 0.1
a Includes all specimen types and all locations in hospitals from 133 institutions.
b Abbreviations: APAC, Asia-Pacific; EU, Europe; AF/ME, Africa-Middle East; LAM, Latin America; NAM, North America.
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ceptibility to fluconazole (75% S) was seen with C. glabrata
(68.7% S), C. krusei (8.6% S), C. guilliermondii (73.5% S), C.
inconspicua (22.6% S), C. rugosa (49.9% S), C. norvegensis
(41.9% S), C. valida (23.8% S), C. humicola (50% S), C. lam-
bica (0% S), C. ciferrii (50% S), and C. marina (0% S). Thus,
despite the fact that overall 90% of all clinical isolates of
Candida were susceptible to fluconazole, these data demon-
strate that 13 of the 31 species identified in this survey exhibit
decreased susceptibility on the order of that seen with the
well-known resistant species C. glabrata and C. krusei.
As noted previously (57), voriconazole was more active than
fluconazole against most species of Candida with the exception
of C. tropicalis (91.0% S to fluconazole versus 89.5% S to
voriconazole); C. apicola (98.2% S to both); C. pulcherrima
(100% S to both); C. haemulonii (88.9% S to both); C. stella-
toidea (85.7% S to both); C. humicola (50% S to both); C.
ciferrii (50% S to both); and C. colliculosa, C. holmii, and C.
sphaerica (100% S to both). C. rugosa (69.3% S to voricon-
azole), C. lipolytica (77.3% S), C. humicola (50% S), C. lambica
(40% S), and C. ciferrii (50% S) were all considerably less
susceptible to voriconazole than were all other species of Can-
dida.
A total of 12,179 isolates encompassing 24 different species
of Candida were found to be resistant to fluconazole (Table 4).
Whereas voriconazole was active (75% S) against flucon-
azole-resistant isolates of C. krusei (79.6% S), C. inconspicua
(83.8% S), C. norvegensis (81.0% S), and C. intermedia (100%
S), activity was quite poor against the remaining 20 species.
Notably, less than 30% of fluconazole-resistant isolates of C.
albicans (28.1% S); C. glabrata (19.1% S); C. tropicalis (17.0%
S); C. rugosa (28.1% S); C. lipolytica (29.7% S); C. pelliculosa
(16.7% S); C. lambica (25% S); and C. apicola, C. haemulonii,
C. humicola, and C. ciferrii (all 0% S) remained susceptible to
voriconazole. Cross-resistance between fluconazole and vori-
conazole is clearly more pronounced in some species of Can-
dida than others, although all are affected to some degree,
emphasizing the importance of both species identification and
antifungal susceptibility testing in settings of candidal infection
with prior azole exposure (1, 32, 42, 43, 57, 65, 66).
Trends in resistance to fluconazole among Candida spp.
over a 10.5-year period. There was no consistent trend toward
increasing resistance to fluconazole detected among the com-
mon species C. albicans, C. glabrata, and C. tropicalis over the
10.5-year time period (Table 5). Likewise, consistently high
levels of resistance were seen among C. krusei, C. inconspicua,
C. norvegensis, and C. valida. Resistance was high among C.
TABLE 3. In vitro susceptibilities of Candida spp. to fluconazole and voriconazole as determined by CLSI disk diffusion testinga
Species
Fluconazoleb Voriconazoleb
No. of isolates
tested % S % R
No. of isolates
tested % S % R
C. albicans 128,625 98.0 1.4 125,965 98.5 1.2
C. glabrata 23,305 68.7 15.7 22,968 82.9 10.0
C. tropicalis 15,546 91.0 4.1 15,198 89.5 5.4
C. parapsilosis 12,788 93.2 3.6 12,453 97.0 1.8
C. krusei 5,079 8.6 78.3 5,005 83.2 7.6
C. guilliermondii 1,410 73.5 11.4 1,375 90.5 5.7
C. lusitaniae 1,233 92.1 5.4 1,215 96.7 2.0
C. kefyr 1,044 96.5 2.7 1,032 98.7 0.9
C. inconspicua 566 22.6 53.2 563 90.6 3.9
C. famata 622 79.1 10.3 606 90.3 5.0
C. rugosa 603 49.9 41.8 580 69.3 21.2
C. dubliniensis 310 96.1 2.6 308 98.4 1.0
C. norvegensis 248 41.9 40.7 247 91.5 4.0
C. lipolytica 130 66.2 28.5 128 77.3 14.1
C. sake 87 85.1 11.5 87 92.0 6.9
C. pelliculosa 87 89.7 6.9 86 94.2 4.7
C. apicola 57 98.2 1.8 57 98.2 1.8
C. zeylanoides 70 67.1 24.3 67 85.1 6.0
C. valida 21 23.8 61.9 22 81.8 13.6
C. intermedia 24 95.8 4.2 25 100.0 0.0
C. pulcherrima 14 100.0 0.0 14 100.0 0.0
C. haemulonii 9 88.9 11.1 9 88.9 11.1
C. stellatoidea 7 85.7 0.0 7 85.7 14.3
C. utilis 6 83.3 0.0 7 100.0 0.0
C. humicola 6 50.0 50.0 6 50.0 33.3
C. lambica 5 0.0 80.0 5 40.0 20
C. ciferrii 2 50.0 50.0 2 50.0 0.0
C. colliculosa 2 100.0 0.0 2 100.0 0.0
C. holmii 1 100.0 0.0 1 100.0 0.0
C. marina 1 0.0 0.0 1 100.0 0.0
C. sphaerica 1 100.0 0.0 1 100.0 0.0
Candida spp.c 9,744 86.2 8.9 9,577 93.6 4.1
a Isolates were obtained from 133 institutions, 2001 to 2007.
b Fluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI document M44-A (7). The interpretive breakpoints (zone diameters)
were as follows: S, 19 mm (fluconazole) and 17 mm (voriconazole); R, 14 mm (fluconazole) and 13 mm (voriconazole).
c Candida species, not otherwise specified.
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famata, C. rugosa, C. lipolytica, and C. zeylanoides for the years
2001 through 2004 but decreased for all four species during
2005 through 2007. Resistance to fluconazole also fell by 50%
for C. kefyr during the latter 3-year period. The reasons for
such decreases in resistance are unclear.
A slight increase in fluconazole resistance was noted among
C. parapsilosis (2.5% to 3.6%), C guilliermondii (9.9% to
14.2%), and C. lusitaniae (2.9% to 6.0%) over the 10.5-year
period. Although the numbers of isolates were small, C. saki
(10.0% to 11.9%), C. pelliculosa (15.0%), C. haemulonii
(33.3%) C. humicola (50%), C. lambica (80%), and C. ciferrii
(50%) all showed elevated rates of resistance over the last 3
years (2005 to 2007).
Trends in resistance to voriconazole among Candida spp.,
2001 to 2007. Voriconazole has been tested in the ARTEMIS
program since its introduction into clinical use in 2001 (Table
6). As noted previously (Table 3), resistance to voriconazole
was uncommon (5%) during each of the study years; how-
ever, a trend toward increased resistance over the most recent
3 years (2005 to 2007) was observed for C. famata (1.1% to
5.7%), C. norvegensis (0.0% to 6.9%), C. lipolytica (0.0% to
11.1%), and C. pelliculosa (14.3% to 16.7%). Notably, there
was no trend toward increased resistance to voriconazole
among the fluconazole-resistant species C. glabrata, C. krusei,
C. guilliermondii, C. rugosa, and C. inconspicua.
Geographic variation in the susceptibilities of Candida to
fluconazole and voriconazole. Table 7 presents the in vitro
susceptibility results for fluconazole and voriconazole tested
against the five most common species of Candida (C. albicans,
C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei) and four
uncommon fluconazole-resistant species (C. guilliermondii, C.
inconspicua, C. rugosa, and C. norvegensis) stratified by geo-
graphic region for the time period from 2001 to 2007. Just as
geographic variation was seen in the frequency of isolation of
these different species (Table 2), considerable variation in the
frequency of azole resistance was observed as well. Although
both fluconazole and voriconazole were highly active against C.
albicans in all geographic regions, considerably higher rates of
resistance to both azoles were detected among isolates from
North America than among those from the other four regions.
Similarly to C. albicans, the highest rates of azole resistance
among isolates of C. glabrata were seen in North America.
C. tropicalis is now recognized as the second most common
species of Candida isolated from patients with invasive candi-
diasis in the Asia-Pacific region (5, 23, 28, 70–75) (Table 2).
Reports from Taiwan have also highlighted the emergence of
fluconazole resistance in C. tropicalis from a variety of different
specimen types (71, 74). These findings are supported by the
most recent ARTEMIS data, where the highest rates of resis-
tance to both fluconazole and voriconazole were seen among
isolates of C. tropicalis from the Asia-Pacific region (Table 7).
The lowest rates of resistance to both azoles were seen with
isolates of C. tropicalis from the Africa/Middle East region. As
noted previously (57), C. tropicalis isolates from all regions,
with the exception of those from the Africa/Middle East re-
gion, were slightly more resistant to voriconazole than to flu-
conazole.
Azole resistance among isolates of C. parapsilosis is gener-
ally considered to be infrequent (59, 69), and that is the case in
all of the regions surveyed in the ARTEMIS program with the
exception of those isolates from the Africa/Middle East region
(Table 7). Whereas resistance to fluconazole and voriconazole
was 5% and 3%, respectively, in Europe, Latin America,
North America, and the Asia-Pacific regions, it was 15.0% and
11.1%, respectively, in the Africa/Middle East region, with the
highest rates seen in isolates from South Africa (21% and 15%,
respectively).
Among the five species of Candida that are recognized as
having decreased susceptibility to fluconazole, C. krusei
showed high-level resistance in all of the geographic regions.
Interestingly, 14% of isolates of C. krusei from Latin America
were resistant to voriconazole compared to only 4.5% to 7.7%
of isolates from other regions.
Isolates of C. guilliermondii from the Asia-Pacific region and
Europe were more resistant to both fluconazole and voricon-
azole than were those from other regions, whereas the highest
rates of resistance to both agents among C. rugosa isolates were
seen in Latin America. The greatest geographic variation in
resistance to voriconazole was noted with C. rugosa, where
32.8% of Latin American isolates were resistant compared to
0% to 11.1% in the other regions.
Both C. inconspicua and C. norvegensis appear predomi-
nately in Europe, and isolates of both species from this region
demonstrate a fluconazole-resistant and voriconazole-suscep-
tible phenotype. Whereas the few isolates of C. inconspicua
from other regions also exhibit this phenotype, isolates of C.
norvegensis from regions other than Europe are generally sus-
ceptible to both azoles.
TABLE 4. In vitro susceptibilities of fluconazole-resistant isolates of
Candida spp. to voriconazole as determined by CLSI
disk diffusion testinga
Species No. of isolatestested % S % SDD % R
C. albicans 1,782 28.1 8.4 63.6
C. glabrata 3,550 19.1 21.7 59.2
C. tropicalis 629 17.0 15.3 67.7
C. parapsilosis 431 39.2 20.4 40.4
C. krusei 3,889 79.6 11.3 9.2
C. guilliermondii 157 43.9 16.6 39.5
C. lusitaniae 63 55.6 17.5 27.0
C. kefyr 27 66.7 7.4 25.9
C. inconspicua 297 83.8 10.1 6.1
C. famata 62 37.1 24.2 38.7
C. rugosa 242 28.1 21.5 50.4
C. dubliniensis 8 62.5 0.0 37.5
C. norvegensis 100 81.0 10.0 9.0
C. lipolytica 37 29.7 27.0 43.2
C. sake 9 44.4 11.1 44.4
C. pelliculosa 6 16.7 16.7 66.7
C. apicola 1 0.0 0.0 100.0
C. zeylanoides 15 46.7 26.7 26.7
C. valida 14 71.4 7.1 21.4
C. intermedia 1 100.0 0.0 0.0
C. haemulonii 1 0.0 0.0 100.0
C. humicola 3 0.0 33.3 66.7
C. lambica 4 25.0 50.0 25.0
C. ciferrii 1 0.0 100.0 0.0
Candida spp.b 850 47.6 14.6 37.8
a Isolates obtained from 133 institutions, 2001 to 2007. The zone diameters for
voriconazole disk diffusion susceptibility categories were as follows: S, 17 mm;
SDD, 14 to 16 mm; R, 13 mm.
b Candida species not otherwise identified.
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Variation in the frequency of isolation and the antifungal
susceptibility profile of C. krusei, C. inconspicua, and C. norve-
gensis by clinical service. C. krusei, C. inconspicua, and C.
norvegensis are uncommon species of Candida that share a
fluconazole-resistant, voriconazole-susceptible phenotype (3,
11, 14, 34, 62). Although C. krusei is well studied, little is known
of the frequency of occurrence and variation in azole suscep-
tibility of C. inconspicua and C. norvegensis according to clin-
ical service (3, 11, 18, 58, 62). The clinical services reporting
the isolation of those three species from patient specimens
included the hematology-oncology service, medical and surgi-
cal services, intensive care units (ICUs; medical-surgical and
neonatal), the dermatology service, the urology service, and
the outpatient service (Table 8). Those strains from services
with only a few isolates and those for which a clinical service
was not specified were included in the category “other, not
otherwise specified” (other, NOS).
C. krusei was isolated most frequently from the hematology-
oncology service and the medical service. Whereas resistance
to fluconazole was elevated in every service, resistance to vori-
conazole was 10% in all services except the neonatal ICU
(13.8% [data not shown]) and the outpatient service (10.1%).
Less than 80% of isolates from the hematology-oncology and
dermatology services were susceptible to voriconazole.
As with C. krusei, C. inconspicua was isolated most fre-
quently from the hematology-oncology and medical services.
Previously, D’Antonio et al. (11) reported a cluster of catheter-
related infections due to C. inconspicua in patients with hema-
tologic malignancies. More than 50% of isolates from the he-
matology-oncology, surgical, ICU, and dermatology services
were resistant to fluconazole, whereas less than 6% of isolates
from all services except dermatology (only 4 isolates tested)
were resistant to voriconazole.
C. norvegensis has been reported as a cause of invasive can-
didiasis among immunosuppressed patients in Denmark and
Norway (62). This species was isolated most frequently from
patients on the medical service, and more than 30% of isolates
from all services except the surgical and dermatology services
were resistant to fluconazole. By comparison, resistance to
voriconazole was uncommon (0% to 4.2%) in all services ex-
cept for the urology service (1 of 6 isolates [16.7%]).
Variation in the frequency of isolation and the antifungal
susceptibility profiles of C. krusei, C. inconspicua, and C. nor-
vegensis by clinical specimen type. The major specimen types
TABLE 5. Trends in in vitro resistance to fluconazole among Candida spp. as determined by CLSI disk diffusion testing
over a 10.5-year perioda,b
Species
1997–2000 2001–2004 2005–2007
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
C. albicans 39,152 0.9 71,027 1.4 57,598 1.4
C. glabrata 5,634 19.2 12,963 15.9 10,342 15.4
C. tropicalis 2,996 3.6 8,496 4.5 7,050 3.6
C. parapsilosis 2,633 2.5 7,783 3.5 5,005 3.6
C. krusei 1,207 65.8 2,840 77.5 2,239 79.3
C. guilliermondii 367 12.5 902 9.9 508 14.2
C. lusitaniae 276 2.9 674 4.3 559 6.6
C. kefyr 182 3.3 527 3.6 517 1.7
C. inconspicua 9 55.6 276 52.2 290 54.1
C. famata 123 17.1 375 12.5 247 6.9
C. rugosa 35 34.3 238 50.7 134 10.4
C. dubliniensis 1 0.0 113 2.7 197 2.0
C. norvegensis 11 54.5 135 36.3 113 46.0
C. lipolytica 7 0.0 80 37.5 50 14.0
C. sake 20 10.0 67 11.9
C. pelliculosa 1 0.0 47 0.0 40 15.0
C. apicola 57 1.8
C. zeylanoides 4 0.0 50 28.0 20 15.0
C. valida 9 66.7 12 58.3
C. intermedia 10 0.0 14 7.1
C. pulcherrima 6 0.0 8 0.0
C. haemulonii 6 0.0 3 33.3
C. stellatoidea 7 0.0
C. utilis 6 0.0
C. humicola 2 50.0 4 50.0
C. lambica 5 80.0
C. ciferrii 2 50.0
C. colliculosa 2 0.0
C. holmii 1 0.0
C. marina 1 0.0
C. sphaerica 1 0.0
Candida spp.c 2,591 10.5 6,186 8.2 3,558 10.1
a Includes all specimen types and all hospital locations in 141 institutions.
b % R, percent resistant (zone diameter, 14 mm).
c Candida species not otherwise identified.
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yielding C. krusei, C. inconspicua, and C. norvegensis as putative
pathogens included blood, normally sterile body fluids
(NSBF), urine, respiratory tract, skin and soft tissue, and gen-
ital specimens (Table 8). Those isolates from uncommon spec-
imen types and those for which as specimen type was not
recorded were grouped under “miscellaneous, NOS.”
C. krusei accounted for 2 to 3% (each) of all Candida spp.
isolated from blood, NSBF, urine, respiratory tract, and skin
and soft tissue specimens. It was isolated infrequently from
genital specimens. Fluconazole resistance was apparent in
70% of isolates from all specimen types, whereas resistance
to voriconazole ranged from 4.5% of isolates from NSBF to
11.4% of isolates from urine. Isolates from blood (86.3% S)
and cerebrospinal fluid (100% S) were more likely to be
susceptible (S) to voriconazole than were those from urine
(76.4% S).
The majority of C. inconspicua isolates reported in the lit-
erature are from the respiratory tract; however, wound, blood,
and genital isolates have also been obtained (3, 11, 33–35).
Whereas the previous reports concerning C. inconspicua con-
tained no more than 50 clinical isolates, the present data set is
considerably more robust and shows C. inconspicua isolated
from numerous body sites, including blood and NSBF. Con-
sistent with the literature, C. inconspicua was isolated most
frequently from the respiratory tract.
Fluconazole resistance among isolates of C. inconspicua
ranged from 26.1% for isolates from skin and soft tissue spec-
imens to 62.9% from genital specimens. Half of all isolates
from NSBF and more than a third of isolates from blood were
resistant to fluconazole. Resistance (R) to voriconazole was
less than 5% for isolates from all specimen types with the
exception of isolates from urine (7.7% R) and miscellaneous
specimen types (5.2% R).
C. norvegensis has been isolated from the oropharynx, blood,
peritoneal fluid, urine, and a variety of deep tissue sites (22, 39,
40, 62, 67). As with C. inconspicua, C. norvegensis was isolated
most frequently from the respiratory tract and with approxi-
mately equal frequency from the other specimen types (Table
9). Whereas isolates from most specimen types were highly
resistant to fluconazole (40% R), isolates from blood (7.7%
R) and skin and soft tissue (8.7% R) were considerably less
resistant. Resistance to voriconazole was quite uncommon (0
to 1.6%) among isolates from all specimen types with the
exception of those from urine (8.7% R) and miscellaneous
specimen types (8.0% R).
TABLE 6. Trends in in vitro resistance to voriconazole among Candida spp. as determined by CLSI disk diffusion
testing over a 7-year perioda,b
Species
2001–2004 2005 2006 2007
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
C. albicans 68,575 1.2 18,630 1.5 18,965 1.0 19,795 1.0
C. glabrata 12,643 10.3 3,185 9.5 3,413 10.2 3,727 9.4
C. tropicalis 8,171 6.1 2,136 4.5 2,317 3.8 2,574 5.1
C. parapsilosis 7,464 1.8 1,581 1.9 1,724 1.3 1,687 1.8
C. krusei 2,765 7.7 684 7.9 742 6.5 814 8.0
C. guilliermondii 872 4.9 184 6.5 155 9.7 164 5.5
C. lusitaniae 655 1.8 163 3.1 195 0.5 202 3.0
C. kefyr 514 0.8 173 2.9 153 0.0 192 0.0
C. inconspicua 274 5.5 77 2.6 89 2.2 123 2.4
C. famata 359 6.4 87 1.1 72 1.4 88 5.7
C. rugosa 446 26.7 33 3.0 38 0.0 63 4.8
C. dubliniensis 111 0.9 57 0.0 70 1.4 70 1.4
C. norvegensis 134 2.2 36 0.0 47 10.4 29 6.9
C. lipolytica 79 17.7 17 0.0 14 14.3 18 11.1
C. sake 20 0.0 13 7.7 27 11.1 27 7.4
C. pelliculosa 47 0.0 14 14.3 19 5.3 6 16.7
C. apicola 44 2.3 13 0.0
C. zeylanoides 48 8.3 7 0.0 2 0.0 10 0.0
C. valida 9 11.1 7 28.6 1 0.0 5 0.0
C. intermedia 10 0.0 8 0.0 3 0.0 4 0.0
C. pulcherrima 6 0.0 2 0.0 4 0.0 2 0.0
C. haemulonii 6 0.0 2 50.0 1 0.0
C. stellatoidea 7 14.3
C. utilis 1 0.0 2 0.0 4 0.0
C. humicola 2 50.0 2 50.0 2 0.0
C. lambica 2 0.0 3 33.3
C. ciferrii 1 0.0 1 0.0
C. colliculosa 1 0.0 1 0.0
C. holmii 1 0.0
C. marina 1 0.0
C. sphaerica 1 0.0
Candida spp.c 6,022 4.7 1,183 4.9 1,031 2.4 1,341 2.0
a Isolates were obtained from 133 institutions.
b % R, percent resistant (zone diameter, 13 mm).
c Candida species not otherwise identified.
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DISCUSSION
There is no lack of data concerning the in vitro susceptibility
of isolates of C. albicans, C. glabrata, C. tropicalis, and C.
parapsilosis to both fluconazole and voriconazole (24, 55). Lon-
gitudinal surveillance studies from individual institutions, cit-
ies, countries, and broad geographic regions document the
sustained activities of these agents versus C. albicans, C. tropi-
calis, and C. parapsilosis and the ongoing potential for C. gla-
brata to develop resistance to both triazoles (2, 10, 12, 17, 27,
46, 55, 63). Using the ARTEMIS database, we have confirmed
and extended these observations globally over a 10.5-year pe-
riod of study.
These four major yeast pathogens vary in frequency of oc-
currence and azole susceptibility over the four geographic re-
gions encompassed in this survey (Tables 2 and 7). Although C.
albicans remains quite susceptible to both azoles, the data
reported herein demonstrate a lower frequency of occurrence
and yet a higher rate of resistance of this species to both
fluconazole and voriconazole in North America compared to
the other regions (Tables 2 and 7). Likewise, C. glabrata re-
mains more common in North America, and isolates from this
region exhibit higher rates of azole resistance than do those
from other parts of the world (Tables 2 and 7). C. tropicalis is
a prominent cause of invasive candidiasis in both the Latin
American and Asia-Pacific regions (Table 2). We have con-
firmed the earlier reports of increased resistance to flucon-
azole among isolates of C. tropicalis from the Asia-Pacific re-
gion (Table 7) (71, 74). C. parapsilosis is well known as an
exogenous cause of catheter-related fungemia (59, 69). Al-
though resistance to fluconazole remains relatively uncommon
(Table 3), there appears to be a slight trend toward increasing
resistance over time (Table 5). Local outbreaks of C. parapsi-
losis fungemia document its role as a nosocomial pathogen
(69), and it is evident that when lapses in infection control
precautions are coupled with broad use of fluconazole, an
endemic, fluconazole-resistant strain of this species may
emerge (6, 64).
The present study extends the list of species of Candida that
may be isolated from clinical specimens (Table 1). Although
many of these species are uncommon, their appearance in this
survey underscores an increased effort by clinical laboratories
worldwide to identify isolates of Candida to the species level.
One limitation of this survey is that most laboratories em-
ployed commercial identification methods that may have prob-
lems identifying the more unusual species (25). Previously we
have been able to validate the identification of many of these
species (47), including cryptic species such as C. dubliniensis, C.
metapsilosis, C. orthopsilosis, C. nivariensis, C. bracarensis, and
C. fermentati (16, 29–31). Unfortunately, with a survey of this
magnitude we have been unable to do so in every case.
Despite the fact that 90% of the more than 250,000 isolates
reported herein remain susceptible to fluconazole, it is impor-
tant to realize that many of the less common species of Can-
dida exhibit decreased susceptibilities to both fluconazole and
voriconazole compared to those of C. albicans, C. tropicalis,
and C. parapsilosis. Furthermore, despite the very potent ac-
tivity and broad spectrum of activity shown by voriconazole
(Table 3), this agent is considerably less active against most
TABLE 7. Geographic variation in the in vitro susceptibilities of common and uncommon species of Candida to fluconazole
and voriconazole, 2001 to 2007a
Species Antifungalagent
APAC EU AF/ME LAM NAM
No. of
isolates % R
No. of
isolates % R
No. of
isolates % R
No. of
isolates % R
No. of
isolates % R
C. albicans Fluconazole 28,781 0.9 74,408 1.3 5,539 0.6 14,178 2.1 5,718 5.1
Voriconazole 27,827 0.8 72,873 1.1 5,502 0.3 13,711 1.7 5,681 3.6
C. glabrata Fluconazole 5,629 13.0 12,439 16.3 728 16.2 2,039 15.1 2,470 19.5
Voriconazole 5,515 8.2 12,288 9.8 705 8.1 2,000 11.3 2,460 14.6
C. tropicalis Fluconazole 5,178 6.5 5,349 2.9 544 2.6 3,625 2.6 850 4.4
Voriconazole 5,062 8.4 5,128 3.9 542 2.4 3,522 3.7 836 5.3
C. parapsilosis Fluconazole 3,294 4.3 4,578 2.6 499 15.0 2,830 2.1 1,587 3.5
Voriconazole 3,120 1.7 4,487 1.1 496 11.1 2,779 0.9 1,517 2.4
C. krusei Fluconazole 532 73.5 3,678 80.8 134 72.4 370 66.8 361 74.0
Voriconazole 516 5.0 3,637 7.7 134 4.5 351 14.0 363 5.5
C. guilliermondii Fluconazole 178 13.5 567 13.8 12 8.3 590 9.0 63 7.9
Voriconazole 175 10.9 558 6.1 12 0.0 567 3.7 63 4.8
C. inconspicua Fluconazole 4 25.0 558 53.0 2 100.0 2 100.0
Voriconazole 4 0.0 555 3.8 2 50.0 2 0.0
C. rugosa Fluconazole 165 32.1 89 10.1 1 0.0 339 55.5 9 22.2
Voriconazole 145 6.9 87 1.1 1 0.0 338 32.8 9 11.1
C. norvegensis Fluconazole 7 14.3 204 49.0 1 0.0 13 0.0 21 0.0
Voriconazole 7 0.0 203 4.9 1 0.0 13 0.0 21 0.0
a For definitions of abbreviations, see Table 2, footnote b.
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fluconazole-resistant isolates (Table 4). Thus, with few excep-
tions, Candida spp. causing infection in patients with previous
fluconazole exposure are very likely to show decreased suscep-
tibility to voriconazole as well (1, 32, 42).
This report highlights the few species that routinely express
a fluconazole-resistant, voriconazole-susceptible phenotype
(Tables 4 and 7 to 9). The most common of these, C. krusei, is
well known, and studies have demonstrated that the voricon-
azole activity against this species may be attributed to en-
hanced binding of this triazole to the target enzyme compared
to that of fluconazole (15, 56, 58). Two additional species, C.
inconspicua and C. norvegensis, share this fluconazole-resistant,
voriconazole-susceptible phenotype (Tables 3 and 4). Al-
though quite uncommon in most regions of the world (Table
TABLE 8. Susceptibilities of C. krusei, C. inconspicua, and C. norvegensis to fluconazole and voriconazole by clinical servicea
Clinical service
(total no. of isolates) Antifungal agent
C. krusei C. inconspicua C. norvegensis
No. of isolates
tested % R
b No. of isolates
tested % R
No. of isolates
tested % R
Hematology-oncology (11,930) Fluconazole 757 83.1 113 51.3 24 50.0
Voriconazole 741 9.6 113 5.3 24 4.2
Medical (47,024) Fluconazole 1,128 79.9 101 42.6 68 33.8
Voriconazole 1,106 7.8 101 4.0 68 2.9
Surgical (12,659) Fluconazole 316 78.5 62 61.3 25 28.0
Voriconazole 320 5.6 62 1.6 25 0.0
ICU (27,758) Fluconazole 706 79.0 78 50.0 26 42.3
Voriconazole 692 6.6 76 2.6 26 0.0
Dermatology (3,001) Fluconazole 32 71.9 4 75.0 2 0.0
Voriconazole 31 6.5 4 50.0 2 0.0
Urology (1,954) Fluconazole 40 60.0 4 25.0 6 83.3
Voriconazole 40 7.5 4 0.0 6 16.7
Outpatient (15,810) Fluconazole 212 74.5 17 23.5 23 34.8
Voriconazole 213 10.3 17 5.9 22 0.0
Other NOS (81,517) Fluconazole 1,888 75.9 187 61.5 74 47.3
Voriconazole 1,862 7.0 186 3.2 74 8.1
a Isolates were obtained from 133 institutions.
b % R, percent resistant (zone diameter, 14 mm fluconazole and 13 mm voriconazole).
TABLE 9. Susceptibilities of C. krusei, C. inconspicua, and C. norvegensis to fluconazole and voriconazole by specimen typea
Specimen type/site
(total no. of isolates) Antifungal agent
C. krusei C. inconspicua C. norvegensis
No. of isolates
tested % R
b No. of isolates
tested % R
No. of isolates
tested % R
Blood (20,704) Fluconazole 459 74.5 24 37.5 13 7.7
Voriconazole 459 8.5 24 4.2 13 0.0
NSBF (8,650) Fluconazole 246 80.5 45 51.1 18 55.6
Voriconazole 243 4.5 45 4.4 18 0.0
Urine (25,881) Fluconazole 518 80.1 26 53.8 23 56.5
Voriconazole 516 11.4 26 7.7 23 8.7
Respiratory tract (56,961) Fluconazole 1,787 79.2 231 51.5 64 42.2
Voriconazole 1,760 7.8 229 2.2 63 1.6
Skin/soft tissue (11,221) Fluconazole 252 81.7 23 26.1 23 8.7
Voriconazole 251 8.0 23 4.3 23 0.0
Genital tract (44,839) Fluconazole 566 71.9 62 62.9 19 52.6
Voriconazole 553 6.9 62 4.8 19 0.0
Miscellaneous NOS (33,397) Fluconazole 1,251 79.2 155 58.7 88 43.2
Voriconazole 1,223 5.8 154 5.2 88 8.0
a Isolates were obtained from 133 institutions.
b % R, percent resistant (zone diameter, 14 mm fluconazole and 13 mm voriconazole).
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2), these two species have been recognized for some time in
Europe as fluconazole-resistant causes of candidal coloniza-
tion and infection (3, 11, 14, 22, 34, 35, 39, 40, 62). Among the
isolates of C. krusei, C. inconspicua, and C. norvegensis in the
present study, it is notable that they appear to be especially
localized to Eastern Europe, namely, Hungary, Russia, and the
Czech Republic. Whereas these three countries account for
21% of the Candida isolates overall, they account for 38% of
all C. krusei, 31% of all C. norvegensis, and 75% of all C.
inconspicua isolates (data not shown). European isolates of C.
inconspicua and C. norvegensis appear to be more resistant to
fluconazole than those from other geographic regions (Table
7). The epidemiological niche for these two species appears to
be similar to that of C. krusei, with infection/colonization seen
more frequently among patients housed in the hematology-
oncology and medical services (Table 8). Whereas these spe-
cies, as well as C. krusei, are often seen as colonizers (3, 22, 58,
62), isolates from blood and NSBF are reported in this survey
(Table 9) and in other reports in the literature (3, 11, 34, 35, 39,
40, 62).
These and other relatively rare species of Candida are un-
likely to be familiar to many clinicians and microbiologists, and
there are few or no data concerning prognosis or optimal
treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).
Given the ubiquitous use of azoles in prophylaxis and empirical
and directed therapies (4, 43, 65, 66), it is important to know
the activities of the systemically active agents, such as flucon-
azole and voriconazole, against these organisms (65, 66). The
less common species of Candida often exhibit decreased sus-
ceptibility to fluconazole and, in some strains, to voriconazole
(Table 3); this is important because these organisms may
emerge as pathogens in immunocompromised patients who
have already been receiving an azole (3, 11, 39, 41, 62, 65).
Whereas most species of Candida that exhibit acquired resis-
tance to fluconazole also appear to be considerably less sus-
ceptible to voriconazole than their wild-type “fluconazole-
naïve” counterparts (Table 4), species such as C. krusei, C.
inconspicua, and C. norvegensis may emerge during fluconazole
therapy due to their intrinsic resistance to fluconazole and yet
remain susceptible to voriconazole (Table 3 and 4).
In summary, we have used the ARTEMIS database to pro-
vide further evidence of the sustained activity of fluconazole
and voriconazole against a broad range of Candida species.
With an ever-expanding array of species causing infection in
highly compromised patients, it is important to understand the
activity of these “workhorse” antifungal agents against both
common and uncommon species. It is comforting to know that
both of these triazoles remain active against many of the more
common species; however, reduced activity of fluconazole may
be seen among the less common species, and resistance to
voriconazole is often encountered among species with ac-
quired fluconazole resistance (Table 4). Continued surveil-
lance, both locally and on a regional and international basis, is
clearly warranted.
Since it is a descriptive and sentinel-based study, there are
certain limitations inherent in the ARTEMIS passive surveil-
lance program that must be acknowledged. Despite a long-
standing protocol for testing and reporting consecutive isolates
from individual infectious episodes, there are no controls for
participant compliance with the isolate submission protocol
from one year to the next. This leads to the possibility that
variations in the frequency of isolation of certain species may
be influenced by financial, human resource, or policy changes
and constraints and may under- or overestimate the true prev-
alence of any given species. Close monitoring of each study
site’s level of participation by the study coordinators using
e-mail and other means of communication represents our ef-
forts to ensure compliance with the data collection protocol.
We recognize that studies of this scope are bound to have some
variation in center participation, and we point out that the
sheer number of submitted isolates from every region should
help minimize individual center effects. Rigorous standardiza-
tion of the CLSI disk diffusion method is ensured by both
internal QC monitoring and external validation of both isolate
identification and antifungal susceptibility results (29–31, 48,
50, 61). Despite these limitations, the overall size of this col-
lection of Candida isolates does provide useful descriptive in-
formation. Such information will continue to be useful as a
basis for comparison for future studies regarding the preva-
lence and antifungal susceptibility of both common and un-
common species of Candida as agents of IC throughout the
world.
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